Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Key Highlights
- ➤Breast cancer vaccine Phase 1 met all primary endpoints in 35 patients.
- ➤74% protocol-specified immune-response rate reported for Anixa's breast cancer vaccine.
- ➤Lira-cel Phase 1 patient survived nearly 2.5 years after treatment.
- ➤Lira-cel current-dose cohort patient showed stable disease at three months.
- ➤Anixa held approximately $14 million cash and short-term investments, with no debt.
Expert Statements
Amit Kumar, Chairman and CEO of Anixa Biosciences
“Early clinical observations include encouraging survival in heavily pretreated patients, with one patient surviving nearly 2.5 years following treatment, and the first patient at the current dose level exhibiting stable disease at three months.”
ORLANDO, FL / ACCESS Newswire / October 13, 2026 / RedChip Companies will host an investor webinar on Tuesday, October 20, 2026, at 4:15 p.m. ET with Anixa Biosciences, Inc. (Nasdaq:ANIX), a clinical-stage biotechnology company developing first-in-class therapies to treat and potentially prevent cancer.
The exclusive event will feature Dr. Amit Kumar, Chairman and CEO, who will discuss Anixa's two clinical-stage oncology programs: lira-cel, a novel CAR-T therapy for recurrent, treatment-resistant ovarian cancer, and a breast cancer vaccine with therapeutic and preventive potential. Both programs are being advanced through collaborations with leading research institutions, Moffitt Cancer Center and Cleveland Clinic.
Get started
Create a free account to read the full story.